PipelineReview.com2h
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its ...
Le Lézard4h
APA GUIDE FOR PARENTS AIMS TO HELP TEENS CHOOSE VIDEO CONTENT MINDFULLY
Teens often spend hours daily watching videos online, but parents should consider how the content affects their well-being ...
Le Lézard4h
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced the successful first close of its Series B ...
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...
Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA
Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...